Asset profile
janagliflozin
Small molecule
Evidence outlook · lead readout
NCT03811548 · Diabetes Type 2
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT03811548: This randomized, double-blind, placebo-controlled trial enrolled 442 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. Both the 25 mg and 50 mg doses of janagliflozin significantly outperformed placebo (p<0.001 for both), exceeding the trial's pre-specified superiority margin.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Janagliflozin: this drug | Phase 3 | Small molecule | SGLT2 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| DWP16001 (Enavogliflozin) | Phase 3 | Small molecule | SGLT2 | ||
| THR-1442 | Phase 3 | Small molecule | SGLT2 | ||
| DA-2811 | Phase 2 | Small molecule | SGLT2 | ||
| Tofogliflozin (Apleway / Deberza) | Phase 2 | Small molecule | SGLT2 | ||
| Rongliflozin | Phase 1 | Small molecule | SGLT2 | ||
| Zibotentan + Dapagliflozin | Phase 3 | Small molecule | Endothelin A receptor, SGLT2 | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.